WallStSmart

AbbVie Inc (ABBV)vsSotera Health Co (SHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 5183% more annual revenue ($62.82B vs $1.19B). SHC leads profitability with a 9.9% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. SHC earns a higher WallStSmart Score of 68/100 (B-).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

SHC

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 4.7Quality: 5.8
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-19.7%)

Margin of Safety

-19.7%

Fair Value

$168.33

Current Price

$201.55

$33.22 premium

UndervaluedFair: $168.33Overvalued
SHCUndervalued (+2.9%)

Margin of Safety

+2.9%

Fair Value

$17.89

Current Price

$15.78

$2.11 discount

UndervaluedFair: $17.89Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV5 strengths · Avg: 9.6/10
Market CapQuality
$358.55B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

SHC3 strengths · Avg: 9.7/10
Operating MarginProfitability
31.3%10/10

Strong operational efficiency at 31.3%

EPS GrowthGrowth
175.4%10/10

Earnings expanding 175.4% YoY

Return on EquityProfitability
22.7%9/10

Every $100 of equity generates 23 in profit

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
98.9x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.8%2/10

Earnings declined 45.8%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

SHC3 concerns · Avg: 3.0/10
PEG RatioValuation
1.684/10

Expensive relative to growth rate

P/E RatioValuation
38.2x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
4.141/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : SHC

The strongest argument for SHC centers on Operating Margin, EPS Growth, Return on Equity.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.

Bear Case : SHC

The primary concerns for SHC are PEG Ratio, P/E Ratio, Debt/Equity. Debt-to-equity of 4.14 is elevated, increasing financial risk.

Key Dynamics to Monitor

SHC carries more volatility with a beta of 1.82 — expect wider price swings.

ABBV is growing revenue faster at 12.4% — sustainability is the question.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SHC scores higher overall (68/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Sotera Health Co

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.

Want to dig deeper into these stocks?